Human Genome Epidemiology Literature Finder
Records 1 - 3 (of 3 Records) |
Query Trace: Shock and Egfr[original query] |
---|
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jun 19 (11): 3068-77. Socinski Mark A, Goldman Jonathan, El-Hariry Iman, Koczywas Marianna, Vukovic Vojo, Horn Leora, Paschold Eugene, Salgia Ravi, West Howard, Sequist Lecia V, Bonomi Philip, Brahmer Julie, Chen Lin-Chi, Sandler Alan, Belani Chandra P, Webb Timothy, Harper Harry, Huberman Mark, Ramalingam Suresh, Wong Kwok-Kin, Teofilovici Florentina, Guo Wei, Shapiro Geoffrey |
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878). Clinical lung cancer 2021 6 22 (6): 541-548. Riess Jonathan W, Reckamp Karen L, Frankel Paul, Longmate Jeffrey, Kelly Karen A, Gandara David R, Weipert Caroline M, Raymond Victoria M, Keer Harold N, Mack Philip C, Newman Edward M, Lara Primo |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted oncology 2021 5 16 (3): 339-355. Yoh Kiyotaka, Hirashima Tomonori, Saka Hideo, Kurata Takayasu, Ohe Yuichiro, Hida Toyoaki, Mellemgaard Anders, Verheijen Remy B, Ou Xiaoling, Ahmed Ghada F, Hayama Manabu, Sugibayashi Ko, Oxnard Geoffrey |
- Page last reviewed:Feb 1, 2024
- Content source: